NASDAQ:TXG | Free Cash Flow | 10x Genomics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31$26.12M$1.6M$24.52M
2025-12-31$40.78M$1.78M$39M
2025-03-31$34.35M$1.89M$32.46M
2024-12-31-$6.75M$2.72M-$9.46M
2024-03-31-$15.73M$2.91M-$18.64M
2023-12-31$25.76M$3.45M$22.31M
2023-03-31-$4.13M$4.56M-$8.68M
2022-12-31$13.72M$39.73M-$26.01M
2022-03-31-$20.8M$28.14M-$48.94M
2021-12-31$5.81M$27.62M-$21.81M
2021-03-31-$4.08M$38.87M-$42.95M
2020-12-31-$130.18M$21.34M-$151.51M
2020-03-31-$2.58M$8.08M-$10.66M
2019-12-31$6.7M$6.56M$144,000.00
2019-03-31$9.32M$9.37M-$49,000.00
2018-12-31-$51M$2.4M-$53.4M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$136.05M$5.94M$130.12M
2024-12-31$6.66M$12.39M-$5.73M
2023-12-31-$15.2M$48.6M-$63.8M
2022-12-31-$33.61M$131.66M-$165.27M
2021-12-31-$21.37M$101.28M-$122.65M
2020-12-31-$217.9M$36.67M-$254.56M
2019-12-31$34.63M$42.74M-$8.12M
2018-12-31-$76.41M$6.28M-$82.69M
2017-12-31-$10.7M$3.76M-$14.46M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.